All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – China will kickstart a phase III trial Feb. 3 to determine whether patients with 2019-nCoV can be treated with Gilead Sciences Inc.’s NUC inhibitor, remdesivir, which was originally developed for Ebola, four days after a U.S. patient was said to have recovered by using the drug candidate.
BioWorld looks at translational medicine, including: Adapting NGS for coronavirus surveillance; Long QT genes mostly short on evidence; Reservoir dogs don’t hunt; Another reason to get a flu shot; Cerebrospinal fluid is early culprit in stroke edema; Different drivers can turn the wheel in glioblastoma’s vicious cycle; From African genomes, big insights with small sample size; Commercial antibodies underwhelm for studies of PP2A; Tau keeps gliomas in check.
BEIJING – The current speed of new developments in the 2019-nCov outbreak is illustrated by a Jan. 28, 2020, press conference in Munich, where Andreas Zapf, head of the infection task force in the Bavarian ministry for health and food safety, briefed reporters on the first confirmed German case.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aspen, Curevac, Follicum, Fuzionaire, ICER, Nanoviricides, Novartis, Predictive Oncology, Quantitative Medicine, Saromics, Vaxart, Ziopharm.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcam, Applied Stemcell, Best Medical International, Bgi, Biofourmis, Conmed, Curetis, Fuzionaire Diagnostics, Healthfirst, Hollister, ImagineMIC, Microsoft, Nationshearing, Transenterix
Keeping you up to date on recent developments in diagnostics, including: Increasing early disease detection; Adapting NGS for coronavirus surveillance; AD and HHV: Still a mystery; Increasing accuracy of malaria diagnoses
The World Health Organization (WHO) has declared a "public health emergency of international concern" over the global outbreak of novel coronavirus (2019-nCoV), reversing a week-ago decision by its International Health Regulations Emergency Committee. The move comes "not because of what is happening in China, but because of what is happening in other countries," said WHO Director General Tedros Adhanom Ghebreyesus, noting his confidence in China’s capacity to control the outbreak. "Our greatest concern is the potential for the virus to spread to countries with weaker health systems, and which are ill-prepared to deal with it," he said.
BEIJING – Chinese regulators are speeding up to approve more test kits for the deadly coronavirus that already has killed 170 people and infected more than 7,700 globally. Companies also are working around the clock to develop better products and maintain supplies.
RSS
